LY-334370 is a selective
5-HT1F receptor agonist which was under development by
Eli Lilly and Company for the treatment of
migraine headaches.
The drug showed efficacy in a phase II clinical trial
but further development was halted due to toxicity detected in animals.
See also
*
CP-135807
CP-135807 is a drug which acts as a potent and selective agonist for the 5-HT1D serotonin receptor, and is used to study the function of this receptor subtype.
See also
* 4-HO-MPMI
* 5-MeO-MPMI
* Eletriptan
Eletriptan, sold under the brand ...
*
Lasmiditan
Lasmiditan, sold under the brand name Reyvow, is a medication used for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. It is not useful for prevention. It is t ...
*
SN-22
References
External links
*
5-HT1F agonists
Eli Lilly and Company brands
Indoles
Piperidines
Benzamides
Fluoroarenes
Abandoned drugs
{{nervous-system-drug-stub